EXEL (Exelixis) Change In Inventory : $4 Mil (TTM As of Sep. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Exelixis Change In Inventory?

Exelixis's change in inventory for the quarter that ended in Sep. 2024 was $-0 Mil. It means Exelixis's inventory increased by $0 Mil from Jun. 2024 to Sep. 2024 .

Exelixis's change in inventory for the fiscal year that ended in Dec. 2023 was $-13 Mil. It means Exelixis's inventory increased by $13 Mil from Dec. 2022 to Dec. 2023 .

Exelixis's Total Inventories for the quarter that ended in Sep. 2024 was $21 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Exelixis's Days Inventory for the quarter that ended in Sep. 2024 was 109.60.

Inventory Turnover measures how fast the company turns over its inventory within a year. Exelixis's Inventory Turnover for the quarter that ended in Sep. 2024 was 0.83.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Exelixis's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 0.04.

Exelixis Change In Inventory Historical Data

The historical data trend for Exelixis's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exelixis Change In Inventory Chart

Exelixis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

-5.73

-21.90

-13.21

-11.68

-12.98

Exelixis Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Inventory	Get a 7-Day Free Trial															-1.69	1.53	1.72	1.36	-0.38

Exelixis Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $4 Mil.

Exelixis (NAS:EXEL) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Exelixis's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	20.8135	/	17.328	*	365 / 4
	=	109.60

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Exelixis's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	17.328	/	20.8135
	=	0.83

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Exelixis's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	20.8135	/	539.542
	=	0.04

Exelixis Change In Inventory Related Terms

Thank you for viewing the detailed overview of Exelixis's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Exelixis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (NAS:EXEL) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

0IJO:UK EX9:Germany EX9:Germany

Address

1851 Harbor Bay Parkway, Alameda, CA, USA, 94502

Website

https://www.exelixis.com

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Executives

Jeffrey Hessekiel	officer: EVP and General Counsel	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Patrick J. Haley	officer: Sr. Vice President, Commercial	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Dana Aftab	officer: CSO/EVP Disc & Trans Research	EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA CA 94502
George Poste	director	515 GALVESTON DR, REDWOOD CITY CA 94063
Maria C Freire	director	C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Christopher J. Senner	officer: EVP and CFO	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Jack L Wyszomierski	director	SCHERING PLOUGH CORP, ONE GIRALDA FARMS, MADISON NJ 07940-1000
David Edward Johnson	director	590 MADISON AVENUE, NEW YORK NY 10022
Julie Smith	director	C/O RAPTOR PHARMACEUTICAL CORP, 9 COMMERCIAL BLVD, SUITE 200, NOVATO CA 94949
Stelios Papadopoulos	director	3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
Alan M Garber	director	3355 MILTON COURT, MOUNTAIN VIEW CA 94040
Amy C. Peterson	officer: EVP Prod Dev & Med Aff & CMO	C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Bob Oliver	director	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Caligan Partners Lp	director, other: See Remarks	515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Tomas J. Heyman	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080